The California company Biosense Webster, Inc. recently announced FDA clearance for their ThermoCool SmartTouch SF catheter. The company bills it as the only commercially available device that includes both contact force technology and a porous tip.
In promotional materials, the company notes using the ThermoCool SmartTouch leads to reduced ablation time and procedure time while also leading to less total energy usage. In particular, overall procedure times are said to drop by nearly 20 percent.
They report an 88 percent success rate in patients with atrial arrhythmia 12 months after the procedure.
When integrated with Biosense Webster’s Carto 3 advanced imaging system, the ThermoCool SmartTouch has the capability to display all real-time parameters of a procedure on a single screen.
In a press release, the manufacturer’s U.S. president, David Shepherd, celebrates the device as fully in line with the company’s mission.
“The launch of the ThermoCool SmartTouch SF catheter reflects our ongoing commitment to addressing unmet needs in the cardiovascular space,” Shepherd says. “With this approval, we are pleased to continue expanding customer access to innovative technologies that facilitate the diagnosis and treatment of patients with heart rhythm disorders.”